COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

CCTG

The California Collaborative Treatment Group (CCTG) is a clinical trials consortium of academic institutions and community-based organizations in Southern California.


Since 1986, the CCTG has conducted high-impact, multi-center, investigator-initiated clinical trials focusing on:
  • HIV treatment and management
  • Risk reduction behavioral interventions
  • Pre-Exposure Prophylaxis (PrEP)
  • The CCTG research team includes clinicians, psychologists, behavioral scientists, biostatisticians, and pharmacology experts.
The CCTG Administrative Core is located at the UCSD AVRC. Collaborators include:

Current funding for the CCTG is provided by the California HIV/AIDS Research Program (CHRP) and backed by the California State Legislature. CHRP fosters outstanding and innovative research that responds to the needs of all people of California, especially those who are often underserved, by accelerating progress in prevention, education, care, treatment, and a cure for HIV/AIDS.

Community members interested in participating in a CCTG study should contact the Screening Coordinator at (619) 543-8080.

Recent Publications and Results

​Study
​Authors
​Publication/Conference
​Title
​CCTG 600
​Jill Blumenthal, MD et al
​International Workshop on HIV & Women
PrEPing for a PrEP Demonstration Project: Understanding Awareness and Perspectives among Women in Southern California
​CCTG 596
Kathleen Jacobson, MD et al​National HIV Prevention Conference​Best Practices for Incentivized Social Network Recruitment for HIV Case Finding
​CCTG 595
Martin Hoenigl, MD et al​2017 Conference on Retroviruses and Opportunistic Infections​Substance-using MSM on HIV Pre-Exposure Prophylaxis Have Better Adherence
​CCTG 595
Michael Dubé, MD et al​18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV​Tenofovir disoproxil fumarate associated with Fanconi syndrome in an HIV uninfected man receiving HIV pre-exposure prophylaxis
​CCTG 595
David Moore, PhD et alHIV Research for Prevention​Randomized Controlled Trial of Daily Text Messages for Adherence to Pre-Exposure Prophylaxis (PrEP) in Men who have Sex with Men and Transgender Women
​CCTG 595
​Jill Blumenthal, MD et alInternational AIDS Society​Text messaging responses correlate with tenofovir-disphosphate dried blood spot concentrations among men who have sex with men on pre-exposure prophylaxis
​CCTG 595
Joel Milam, PhD et al​​International AIDS SocietyRisk compensation among men who have sex with men (MSM) in Southern California following the initiation of pre-exposure prophylaxis (PrEP)
​CCTG 595
Sheldon Morris, MD MPH et al​National Summit HCV and HIV Diagnosis, Prevention, and Access to Care​Comparison of behavioral factors in men who have sex with men who go on HIV pre-exposure prophylaxis by partner status
​CCTG 595
Eric Ellorin, et al​Infectious Diseases Society of America​Barriers to Health Insurance Coverage and Intention to Continue Pre-Exposure Prophylaxis (PrEP) Reported by Men who have Sex with Men (MSM) in a PrEP Demonstration Project
​CCTG 593
​Katya Corado, MD et al​National HIV Prevention Conference
Can We Improve HIV Prevention Services?: Understanding the Rationale for Expressed Lack of Interest in PrEP in Recently HIV-tested Individuals
​CCTG 592
​Sara Gianella, MD et alBMC Infectious Diseases​Genital Epstein Barr Virus is associated with Higher Prevalence and Persistence of Anal Human Papilloma Virus in HIV-Infected Men on Antiretroviral Therapy
​CCTG 590
Nadejda Beliakova-Bethell, PhD et al​Antiviral ResearchMaraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression
​CCTG 589
Maile Karris, MD et al​HIV Clinical TrialsHIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen
​CCTG 589
Maile Karris, MD et alJournal of Acquired Immune Deficiency Syndromes​Nucleoside-sparing Regimens with Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue